(888) 352-RUSH for help arranging an appointment.
Faculty Rank: Professor
Medical or Graduate Education:
Rush Medical College
Rush University Medical Center - Internal Medicine
Indiana University School of Medicine - Medical Oncology
Breast cancer treatments
Mechanisms of resistance and sensitivity to targeted therapies for breast cancer
Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW Jr, Sparano JA, Davidson NE, Badve SS. Clin Cancer Res. 2013 2013 Mar 1 19(5):1281-9. doi: 10.1158/1078-0432.CCR-12-3029. Epub 2013 Jan 22. HER2-directed treatment of metastatic breast cancer: unanswered questions. Rao R, Cobleigh M. Oncology (Williston Park). 2013 2013 Mar 27(3):176, 178, 180. No abstract available. Adjuvant endocrine therapy for breast cancer. Rao RD, Cobleigh MA. Oncology (Williston Park). 2012 2012 Jun 26(6):541-7, 550, 552 passim. Review. Other options in the treatment of advanced breast cancer. Cobleigh MA. Semin Oncol. 2011 Jun 38 Suppl 2:S11-6 Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H Clin Cancer Res 2011 Jan 15 17(2):372-81 Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group Rao RD, Cobleigh MA, Gray R, Graham ML 2nd, Norton L, Martino S, Budd GT, Ingle JN, Wood WC Med Oncol 2010 Sep 28 Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP Breast Cancer Res Treat 2009 May 115(1):115-21 ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast Taylor ME, Haffty BG, Rabinovitch R, Arthur DW, Halberg FE, Strom EA, White JR, Cobleigh MA, Edge SB Int J Radiat Oncol Biol Phys 2009 Mar 15 73(4):997-1002 Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD; ECOG 2100 J Clin Oncol 2008 Oct 1 26(28):4672-8 Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD J Clin Oncol 2008 Apr 10 26(11):1810-6
To watch a brief video of Melody A. Cobleigh, MD, click the play button at the lower left corner of the video frame below.
(If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
We were part of the original group of investigators looking at a new treatment for breast cancer called Herceptin. And we were dealing with some patients who were extremely ill who got better right before our eyes. And that was one of the most rewarding experiences of my life in medicine. That medication was approved about 10 years ago, and now it’s part of the standard of care for breast cancer. And Rush was right in on the ground floor. It’s pretty neat to be taking a chance on a new treatment strategy not involving chemotherapy, surgery or radiation. We like the idea of using the patient’s own immune system to help fight her cancer, and we watch tumors basically melt away over a period of a week or two.